In response to Fogarty et al. and why adjuvant whole brain radiotherapy is not recommended routinely
Abstract The routine use of adjuvant whole brain radiotherapy (AWBRT) after surgery or stereotactic radiosurgery is now discouraged by a number of international expert panels. Three decades of randomised studies have shown that, although AWBRT improves radiological measures of intracranial disease c...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-11-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12885-017-3672-z |
| _version_ | 1818514026238312448 |
|---|---|
| author | Mark B. Pinkham Arjun Sahgal Andrew P. Pullar Matthew C. Foote |
| author_facet | Mark B. Pinkham Arjun Sahgal Andrew P. Pullar Matthew C. Foote |
| author_sort | Mark B. Pinkham |
| collection | DOAJ |
| description | Abstract The routine use of adjuvant whole brain radiotherapy (AWBRT) after surgery or stereotactic radiosurgery is now discouraged by a number of international expert panels. Three decades of randomised studies have shown that, although AWBRT improves radiological measures of intracranial disease control, the clinical benefit is unclear and it is also associated with inferior quality of life and neurocognitive function. The number of patients with melanoma in these trials was low, but data suggesting that treatment-related side effects should vary according to histology of the primary malignancy are lacking. For metastatic melanoma, the role of AWBRT to control microscopic disease in the brain is also a less relevant concern because systemic therapies with intracranial activity are now available. Whether AWBRT is useful in select patients deemed at high risk of neurologic death remains undefined. |
| first_indexed | 2024-12-11T00:09:36Z |
| format | Article |
| id | doaj.art-71d9b711b22b4515aebac675c7bde716 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-11T00:09:36Z |
| publishDate | 2017-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-71d9b711b22b4515aebac675c7bde7162022-12-22T01:28:12ZengBMCBMC Cancer1471-24072017-11-011711410.1186/s12885-017-3672-zIn response to Fogarty et al. and why adjuvant whole brain radiotherapy is not recommended routinelyMark B. Pinkham0Arjun Sahgal1Andrew P. Pullar2Matthew C. Foote3Department of Radiation Oncology, Princess Alexandra HospitalDepartment of Radiation Oncology, Sunnybrook Health Sciences Centre, University of TorontoDepartment of Radiation Oncology, Princess Alexandra HospitalDepartment of Radiation Oncology, Princess Alexandra HospitalAbstract The routine use of adjuvant whole brain radiotherapy (AWBRT) after surgery or stereotactic radiosurgery is now discouraged by a number of international expert panels. Three decades of randomised studies have shown that, although AWBRT improves radiological measures of intracranial disease control, the clinical benefit is unclear and it is also associated with inferior quality of life and neurocognitive function. The number of patients with melanoma in these trials was low, but data suggesting that treatment-related side effects should vary according to histology of the primary malignancy are lacking. For metastatic melanoma, the role of AWBRT to control microscopic disease in the brain is also a less relevant concern because systemic therapies with intracranial activity are now available. Whether AWBRT is useful in select patients deemed at high risk of neurologic death remains undefined.http://link.springer.com/article/10.1186/s12885-017-3672-zBrain metastasesMelanomaRadiosurgeryGamma knifeWhole brain radiotherapy |
| spellingShingle | Mark B. Pinkham Arjun Sahgal Andrew P. Pullar Matthew C. Foote In response to Fogarty et al. and why adjuvant whole brain radiotherapy is not recommended routinely BMC Cancer Brain metastases Melanoma Radiosurgery Gamma knife Whole brain radiotherapy |
| title | In response to Fogarty et al. and why adjuvant whole brain radiotherapy is not recommended routinely |
| title_full | In response to Fogarty et al. and why adjuvant whole brain radiotherapy is not recommended routinely |
| title_fullStr | In response to Fogarty et al. and why adjuvant whole brain radiotherapy is not recommended routinely |
| title_full_unstemmed | In response to Fogarty et al. and why adjuvant whole brain radiotherapy is not recommended routinely |
| title_short | In response to Fogarty et al. and why adjuvant whole brain radiotherapy is not recommended routinely |
| title_sort | in response to fogarty et al and why adjuvant whole brain radiotherapy is not recommended routinely |
| topic | Brain metastases Melanoma Radiosurgery Gamma knife Whole brain radiotherapy |
| url | http://link.springer.com/article/10.1186/s12885-017-3672-z |
| work_keys_str_mv | AT markbpinkham inresponsetofogartyetalandwhyadjuvantwholebrainradiotherapyisnotrecommendedroutinely AT arjunsahgal inresponsetofogartyetalandwhyadjuvantwholebrainradiotherapyisnotrecommendedroutinely AT andrewppullar inresponsetofogartyetalandwhyadjuvantwholebrainradiotherapyisnotrecommendedroutinely AT matthewcfoote inresponsetofogartyetalandwhyadjuvantwholebrainradiotherapyisnotrecommendedroutinely |